These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7740050)

  • 21. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model.
    Tejedor-Real P; Micó JA; Smadja C; Maldonado R; Roques BP; Gilbert-Rahola J
    Eur J Pharmacol; 1998 Jul; 354(1):1-7. PubMed ID: 9726624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    Valverde O; Blommaert AG; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1995 Nov; 286(1):79-93. PubMed ID: 8566154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
    Durieux C; Ruiz-Gayo M; Roques BP
    Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice.
    Derrien M; Noble F; Maldonado R; Roques BP
    Neurosci Lett; 1993 Oct; 160(2):193-6. PubMed ID: 8247353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceruletide suppresses rotational behavior in lesioned rats via CCKA receptors.
    Fujisawa M; Miyamoto O; Itano T; Tokuda M; Matsui H; Nagao S; Negi T; Hatase O
    Eur J Pharmacol; 1993 Jul; 238(1):127-30. PubMed ID: 8405076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264.
    Dauge V; Bohme GA; Crawley JN; Durieux C; Stutzmann JM; Feger J; Blanchard JC; Roques BP
    Synapse; 1990; 6(1):73-80. PubMed ID: 2399491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
    Vasar E; Stephenson JD; Meldrum BS
    Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity.
    Jagerschmidt A; Guillaume-Rousselet N; Vikland ML; Goudreau N; Maigret B; Roques BP
    Eur J Pharmacol; 1996 Jan; 296(1):97-106. PubMed ID: 8720482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrindole, an opioid delta antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat.
    Ossipov MH; Kovelowski CJ; Vanderah T; Porreca F
    Neurosci Lett; 1994 Nov; 181(1-2):9-12. PubMed ID: 7898778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opposite role of delta 1- and delta 2-opioid receptors activated by endogenous or exogenous opioid agonists on the endogenous cholecystokinin system: further evidence for delta-opioid receptor heterogeneity.
    Noble F; Fournie-Zaluski MC; Roques BP
    Neuroscience; 1996 Dec; 75(3):917-26. PubMed ID: 8951884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
    J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding.
    Ruiz-Gayo M; Baamonde A; Turcaud S; Fournie-Zaluski MC; Roques BP
    Brain Res; 1992 Feb; 571(2):306-12. PubMed ID: 1319268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol.
    Higgins GA; Joharchi N; Wang Y; Corrigall WA; Sellers EM
    Brain Res; 1994 Mar; 640(1-2):246-54. PubMed ID: 8004452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
    Boyle SJ; Tang KW; Woodruff GN; McKnight AT
    Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment.
    Cordonnier L; Sanchez M; Roques BP; Noble F
    Neuroscience; 2005; 135(1):1-10. PubMed ID: 16084652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antinociceptive and gastrointestinal transit effects of cholecystokinin (CCK-8) and related analogs of CCK-8 in the mouse.
    Ayres EA; Parkhurst DN; Fang S; Kramer TH; Hruby VJ; Burks TF
    Proc West Pharmacol Soc; 1991; 34():477-84. PubMed ID: 1788334
    [No Abstract]   [Full Text] [Related]  

  • 38. Characterization of SNF 9007, a novel cholecystokinin/opoid ligand in mouse ileum in vitro: evidence for involvement of cholecystokininA and cholecystokininB receptors in regulation of ion transport.
    Rao RK; Levenson S; Fang SN; Hruby VJ; Yamamura HI; Porreca F
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1003-9. PubMed ID: 8113956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
    Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
    J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins.
    Nichols ML; Bian D; Ossipov MH; Malan TP; Porreca F
    Neurosci Lett; 1996 Sep; 215(3):161-4. PubMed ID: 8899738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.